Aripiprazole: pharmacology, efficacy, safety and tolerability

References

• Oshiro Y, Sato S, Kurahashi N, Tanaka T. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-Phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolone derivatives. J. Med. Chem. 41, 658–667 (1998).
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Tottori K, Uwahodo Y et al. 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 274, 329–336 (1995).
   PubMed Web of Science ®Google Scholar
• Yamada S, Harano M, Yokoo H, Tanaka M. Antagonistic effects of OPC-14597, a novel antipsychotic drug, on quinpirole- and (-)-sulpiride-induced changes in evoked dopamine release in rat striatal slices. J. Pharm. Pharmacol 49, 206–208 (1997).
   PubMed Web of Science ®Google Scholar
• Aihara K, Shimada J, Miwa T et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenyl cyclase activity and prolactin release. Brain Res. 1003, 9–17 (2004).
   PubMed Web of Science ®Google Scholar
• Lawler CP, Prioleau C, Lewis MM, Mak C. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20(6), 612–627 (1999).
   PubMed Web of Science ®Google Scholar
• Matsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacology 146, 139–143 (1999).
   PubMed Web of Science ®Google Scholar
• Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302, 381–389 (2002).
   PubMed Web of Science ®Google Scholar
• Nakai S, Hirose T, Uwahodo Y et al. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. Eur. J. Psychopharmacol. 472, 89–97 (2003).
   Google Scholar
• Inoue T, Domae M, Yamada K, Furukawa T. Effects of the novel antipsychotic agent 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J. Pharmacol. Exp. Ther. 277, 137–143 (1996).
   PubMed Web of Science ®Google Scholar
• Yokoi F, Grunder G, Biziere K et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27(2), 248–259 (2002).
   PubMed Web of Science ®Google Scholar
• Jordan S, Koprivica V, Chen R et al. The antipsychotic aripiprazole is a potent, partial agonist at the 5-HT1A receptor. Eur. J. Psychopharmacol. 441, 137–140 (2002).
   Google Scholar
• Marona-Lewicka D, Nichols DE. Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY-293284 in the drug discrimination assay in rats. Psychopharmacology 472, 415–421 (2004).
   Google Scholar
• Jordan S, Tadori Y, McQuade RD, Yocca F, Kikuchi T. Definitive evidence that aripiprazole is a D2 and 5HT 1A partial agonist [NR565]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17–22 (2003).
   Google Scholar
• Shapiro DA, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400–1411 (2003).
   PubMed Web of Science ®Google Scholar
• DeLeon A, Patel NC, Crismon ML. Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin. Ther. 26(5), 649–666 (2004).
   PubMed Web of Science ®Google Scholar
• Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, Part 1: ‘Goldilocks’ actions at dopamine receptors. J. Clin. Psychiatry 62(11), 841–842 (2001).
   PubMed Web of Science ®Google Scholar
• Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotics: occupancy is not just antagonism. Arch. Gen. Psychiatry 60, 974–977 (2003).
   PubMed Web of Science ®Google Scholar
• Vachharajani N, Vanderslice T, Kollia G et al. Bioavailability of an oral solution of the antipsychotic aripiprazole ([2004]NR608). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• Boulton D, Dressler D, Lullia G et al. An orally-disintegrating tablet formulation or the antipsychotic aripiprazole ([2004]NR606). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• Daniel DG, Stock EG, Wilber CH et al. Intramuscular aripiprazole in acutely agitated psychotic patients ([2004NR612). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• Modell S, Daniel D, Stock E et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S416 (2004).
   Google Scholar
• Mallikaarjun S, Salazar DE, Bramer SL. Time of dosing and food effects on aripiprazole pharmacokinetics [NR564]. Presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17–22 (2003).
   Google Scholar
• Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J. Clin. Pharmacol. 44, 179–187 (2004).
   PubMed Web of Science ®Google Scholar
• Bramer SL, Shoaf S, Salazar DE, Mallikaarjan S. Renal and hepatic impairment of the pharmacokinetics of aripiprazole [NR548]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17–22 (2003).
   Google Scholar
• Citrome L, Josiassen R, Bark N, Brown KS, Mallikaarjun S, Salazar DE. Pharmacokinetics and safety of aripiprazole and concomitant mood stabilizers. Int. J. Neuropsychopharmacol. 5(Suppl. 1), S187 (2002).
   Google Scholar
• DelBello MP, Barzman DH, Kowatch RA et al. Aripiprazole for pediatric bipolar disorder: a retrospective chart review ([2004]NR137). Presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• Streim JE, Breder C, Swanink R et al. Flexible-dose aripiprazole in psychosis of Alzheimer’s dementia ([2004]NR385). Presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• De Deyn PP, Jeste DV, Auby P et al. Aripiprazole for psychosis of Alzheimer’s disease [NR363]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA May 17–22 (2003).
   Google Scholar
• Breder C, Swanink R, Marcus RN, Kostic S. Dose-ranging study of aripiprazole in patients with Alzheimer’s dementia ([2004]NR645). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• Goforth HW, Rao M, Sucholeiki R. Chronic interictal psychosis responsive to aripiprazole. J. Clin. Psychopharmacol. 24(5), 573–574 (2004).
   PubMed Web of Science ®Google Scholar
• Staller JA. Aripiprazole in an adult with Asperger disorder. Ann. Pharmacother. 37, 1628–1631 (2003).
   PubMed Web of Science ®Google Scholar
• Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can. J. Psychiatry 48(11), 771–772 (2003).
   PubMed Web of Science ®Google Scholar
• Myers WC, Ruiz R. Aripiprazole and psychotherapy for delusional disorder, erotomanic type. J. Am. Acad. Child Adolesc. Psychiatry 43(9), 1069–1070 (2004).
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60, 681–690 (2003).
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 63(9), 763–771 (2002).
   PubMed Web of Science ®Google Scholar
• Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new typical antipsychotic: Phase 2 clinical trial result. Eur. Neuropsychopharmacol. 7(Suppl. 2), S227 (1997).
   Google Scholar
• Daniel DG, Saha AR, Ingenito G et al. Aripiprazole, a novel antipsychotic: overview of a Phase II study result. Int. J. Neuropsychopharmacol. 3(Suppl. 1), S157 (2000). Cited in: DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin. Ther. 26, 649–666 (2004).
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. 6, 325–337 (2003).
   PubMed Web of Science ®Google Scholar
• Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J. Clin. Psychiatry 64, 1048–1056 (2003).
   PubMed Web of Science ®Google Scholar
• Casey DE, Carson WH, Saha AR et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology 166, 391–399 (2003).
   PubMed Web of Science ®Google Scholar
• Gismondi R, Meltzer HY, Kujawa M et al. Aripiprazole versus perhenazine in treatment-resistant schizophrenia. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S416 (2004).
   Google Scholar
• Kane JM, Carson WH, Kujawa MJ et al. Aripiprazole versus perphenazine in treatment-resistant schizophrenia [NR537]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17–22 (2003).
   Google Scholar
• Tandon R, Stock EG, Riera L et al. A naturalistic trial with aripiprazole in a general psychiatric setting ([2004]NR603). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• Stock EG, Archibald DG, Tourkodimitris S et al. Long-term effects of aripiprazole on affective symptoms of schizophrenia [NR558]. Presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17–22 (2003).
   Google Scholar
• Immaculada O, Stock E, Archibald D et al. Long-term effects of aripiprazole on affective symptoms of schizophrenia. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S417 (2004).
   Google Scholar
• Marder S, Archibald D, Manos G et al. Long-term effects of aripiprazole therapy on the negative symptoms of schizophrenia. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S243 (2004).
   PubMed Web of Science ®Google Scholar
• Dillenschneider A, Marcus R, Kostic D et al. Short- and long-term effects of aripiprazole treatment on the excitement/hostility symptoms of schizophrenia. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S243 (2004).
   PubMed Web of Science ®Google Scholar
• Carson WH, Archibald DG, Manos G, Marcus RN, Kostic D, Stock EG. Short-term efficacy of aripiprazole on depression and anxiety in schizophrenia ([2004]NR549). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• Jody D, Tandon R, Stock E et al. A naturalistic study of aripiprazole treatment in a general psychiatric setting. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S242 (2004).
   Google Scholar
• Keck PE, Marcus R, Tourkodimitris S et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry 160, 1651–1658 (2003).
   PubMed Web of Science ®Google Scholar
• Sachs GS, Sanchez R, Marcus RN et al. Aripiprazole versus placebo in patients with an acute manic or mixed episode ([2004]NR742). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• McQuade RD, Sanchez R, Carson WH et al. Efficacy of aripiprazole versus placebo in acute mania: pooled analysis ([2004]NR795). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• Jody D, McQuade RD, Carson WH et al. Efficacy of aripiprazole in subpopulations of bipolar disorder ([2004]NR811). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• Keck PE, Sanchez R, Marcus RN et al. Aripiprazole for relapse prevention in bipolar disorder in a 26-week trial ([2004]NR746). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• Sanchez R, Bourin MS, Auby P et al. Aripiprazole vs. haloperidol for maintained treatment effect in acute mania. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S243 (2004).
   PubMed Web of Science ®Google Scholar
• Bilal LA, Patkar AA, Mattila-Evenden M, Peindl KS, Stein-Marcus K, Masand PS. Aripiprazole as an augmentation agent in treatment-resistant depression ([2004]NR136). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• Worthington JW, Fava M, Hughes ME et al. Aripiprazole as an augmentor of SSRIs in mood and anxiety disorder patients [NR196]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17–22 (2003).
   Google Scholar
• Hellerstein DJ. Aripiprazole as an adjunctive treatment for refractory major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 1347–1348 (2004).
   PubMed Web of Science ®Google Scholar
• Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann. Clin. Psychiatry 16, 189–194 (2004).
   PubMedGoogle Scholar
• Connor DM, Payne VM, Gadde KM et al. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J. Clin. Psychiatry 66(1), 49–51 (2005).
   PubMed Web of Science ®Google Scholar
• Marcus RN, Carson WH, McQuade RD et al. Overview of safety and tolerability of aripiprazole in acute mania ([2004]NR796). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• Marder SR, McQuade RD, Stock E et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Res. 61, 123–136 (2003).
   PubMed Web of Science ®Google Scholar
• Jody D, Saha AR, Iwamoto T, Biswas D. Meta-analysis of weight effects with aripiprazole. Int. J. Neuropsychopharmacol. 5(Suppl. 1), S186 (2002).
   Google Scholar
• Kujawa M, McQuade R, Jody D, Carson W. Long-term weight effects of aripiprazole versus olanzapine in a 26-week double-blind study. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S234 (2004).
   Google Scholar
• Carson W, Saha AR, Iwamoto T, Lin C, Kujawa MJ. Meta-analysis of prolactin effects with aripiprazole. Int. J. Neuropsychopharmacol. 5(Suppl. 1), S186 (2002).
   Google Scholar
• Stock E, Saha AR, Brunell R, Archibald DG, Iwamoto T, McQuade RD. Meta-analysis of cardiac safety with aripiprazole. Int. J. Neuropsychopharmacol. 5(Suppl. 1), S186 (2002).
   Google Scholar
• Saha A, Ali MW, Ingenito GG, Wilber R, Luo X, Bramer S. Safety and tolerability of aripiprazole at doses higher than 30 mg. Int. J. Neuropsychopharmacol. 5(Suppl. 1), S185 (2002).
   Google Scholar
• Gentile S. Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann. Pharmacother. 38, 1265–1271 (2004).
   PubMed Web of Science ®Google Scholar
• Lawson WB, Carson WH, Lam S, Abou-Gharbia N, Marcus RN, Kaplita S. Safety of aripiprazole in patients with schizophrenia grouped by race [NR 577]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17–22 (2003).
   Google Scholar
• L’Italien G, Tandon R, Han J, Li H, Ray S, Carson W. Schizophrenic patients show improved overall effectiveness with aripiprazole treatment compared to atypical antipsychotics. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S417 (2004).
   Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2), 596–601 (2004).
   PubMed Web of Science ®Google Scholar
• Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Res. 70, 1–17 (2004).
   PubMed Web of Science ®Google Scholar
• Casey DE, L’Italien GJ, Cislo P. Incidence of metabolic syndrome in olanzapine and aripiprazole patients ([2004]NR338). Presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• McQuade RD, Stock E, Marcus R et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry 65(Suppl. 18), 47–56 (2004).
   PubMed Web of Science ®Google Scholar
• Casey DE, L’Italien G, Waldeck R, Cislo P, Carson WH. Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo [NR733]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17–22 (2003).
   Google Scholar
• Litman RE, Maiorca M, Courage E, Collin C. BMI glucose lipids in patients with schizophrenia before and after aripiprazole ([2004]NR599). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• Littrell KH, Petty RG, Hilligoss NM, Kirshner C, Johnson CG. The effect of aripiprazole on insulin resistance in schizophrenia ([2004]NR602). Presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1–6 (2004).
   Google Scholar
• Casey D, Stock E, Jody D et al. Long-term treatment with aripiprazole: effects on plasma lipid levels and glycaemic control. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S417 (2004).
   Google Scholar
• Weiden PJ, Waldeck R, Tafesse E, Cislo P, L’Italien G, Carson WH. Aripiprazole is not associated with increased diabetes risk: a long-term model [NR738]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17–22 (2003).
   Google Scholar
• Blonde L, L’Italien G, Hardy S, Archibald D, Carson W. Pooled randomized schizophrenia trials show greater long-term diabetes risk with olanzapine than aripiprazole treatment. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S242 (2004).
   Google Scholar
• Stroup TS, McEvoy JP, Swartz MS et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bull. 29(1), 15–31 (2003).
   PubMed Web of Science ®Google Scholar